Each year, some babies experience a lack of oxygen before or during birth, which can lead to brain injury—a medical condition ...

Whole-body hypothermia within hours of birth failed to improve outcomes in preterm infants less than 36 weeks' gestational age with hypoxic-ischemic encephalopathy. Death or moderate or severe ...

In preclinical models, erythropoietin improves regeneration of brain tissue after the acute phase of hypoxic–ischemic injury by enhancing neurogenesis, oligodendrogenesis, and angiogenesis 7,35 ...

Hypoxic ischemic encephalopathy occurs when too little oxygen is going to the brain and other vital organs at or near time of birth. The multicenter trial of 500 infants with moderate or severe ...

Hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of newborn mortality and morbidity worldwide, and lowering the baby's body temperature—called therapeutic hypothermia—is ...

Opens in a new tab or window Erythropoietin was no help for newborns with hypoxic-ischemic encephalopathy already undergoing therapeutic hypothermia in the phase III HEAL trial. Combined death or ...

The Company’s lead candidate, RLS-0071 (pegtarazimod), has received FDA Orphan Drug Designation and Fast Track Designations for hypoxic ischemic encephalopathy (HIE), a devastating disease that ...